Skip to main content

Market Overview

Why CRISPR Therapeutics Stock Is Tumbling Today

Why CRISPR Therapeutics Stock Is Tumbling Today

CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-cell malignancies.

“We are excited to share positive data from our CARBON trial, which show that CTX110 could offer patients with large B-cell lymphomas an immediately available ‘off-the-shelf’ therapy with efficacy similar to autologous CAR-T and a differentiated safety profile,” said Samarth Kulkarni, CEO of CRISPR Therapeutics.

Kulkarni continued, “Furthermore, we have the potential to improve upon already observed efficacy with a consolidation dosing strategy. Based on these encouraging results, we are planning to expand CARBON into a potentially registrational trial in the first quarter of 2022.”

CRISPR Therapeutics is a gene-editing company that is engaged in the development of CRISPR and Cas9-based therapeutics.

CRSP Price Action: CRISPR Therapeutics has traded as high as $220.20 and as low as $84.38 over a 52-week period.

The stock was down 8.62% at $93.75 at time of publication.


Related Articles (CRSP)

View Comments and Join the Discussion!

Posted-In: Samarth Kulkarni why it's movingNews

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at